Back to results
US 2004/0265288 A1Published application
New applications of gene therapy technology
OwnerMichael Z. Gilmaninventor
Life of this patent
Estimating the term…
Abstract
This invention provides new applications of regulated gene therapy relating to treatment of cancer and other disorders.
Claims23
A cell containing
- (a) a first DNA construct or pair of first DNA constructs encoding chimeric proteins comprising (i) at least one receptor domain capable of binding to a selected ligand and (ii) another protein domain, heterologous with respect to the receptor domain, and
- (b) a target gene encoding an angiogenesis inhibitor under the expression control of a transcriptional control element responsive to binding of ligand to the ligand binding domain.
A cell containing
- (a) a first DNA construct or pair of first DNA constructs encoding chimeric proteins comprising (i) at least one receptor domain capable of binding to a selected ligand and (ii) another protein domain, heterologous with respect to the receptor domain, and
- (b) a target gene encoding a tumor specific antigen under the expression control of a transcriptional control element responsive to binding of ligand to the ligand binding domain.
A cell containing
- (a) a DNA construct encoding a chimeric protein consisting essentially of (i) a receptor domain capable of binding to a selected ligand, (ii) a transcription activation domain, heterologous with respect to the receptor domain, (iii) and a DNA binding domain;
- and
- (b) a target gene encoding beta-interferon or a cytokine under the expression control of a transcriptional control element responsive to binding of ligand to the ligand binding domain.
A recombinant virus containing
- (a) a first DNA construct or pair of first DNA constructs encoding chimeric proteins comprising (i) at least one receptor domain capable of binding to a selected ligand and (ii) another protein domain, heterologous with respect to the receptor domain, and
- (b) a target gene encoding an angiogenesis inhibitor, a tumor specific antigen, a cytokine or beta-interferon under the expression control of a transcriptional control element responsive to binding of ligand to the ligand binding domain.
A method for rendering cells capable of regulatable expression of a target gene following exposure of the cells to a selected ligand, which method comprises introducing into the cells:
- (a) a first DNA construct or pair of first DNA constructs encoding chimeric proteins comprising (i) at least one receptor domain capable of binding to a selected ligand and (ii) another protein domain, heterologous with respect to the receptor domain, and
- (b) a target gene under the expression control of a transcriptional control element responsive to binding of ligand to the ligand binding domain,
- wherein the target gene encodes an angiogenesis inhibitor or a tumor specific antigen.
A method for rendering cells capable of regulatable expression of a target gene following exposure of the cells to a selected ligand, which method comprises introducing into the cells:
- (a) a DNA construct encoding a chimeric protein consisting essentially of (i) a receptor domain capable of binding to a selected ligand, (ii) a transcription activation domain, heterologous with respect to the receptor domain, (iii) and a DNA binding domain;
- and
- (b) a target gene encoding beta-interferon or a cytokine under the expression control of a transcriptional control element responsive to binding of ligand to the ligand binding domain.
A method for treating cancer in a mammalian host organism containing cells which:
- contain (a) a first DNA construct or pair of first DNA constructs encoding chimeric proteins comprising (i) at least one receptor domain capable of binding to a selected ligand and (ii) another protein domain, heterologous with respect to the receptor domain, and
- (b) a target gene under the expression control of a transcriptional control element responsive to binding of ligand to the ligand binding domain;
- and
- which express the target gene, following exposure to the selected ligand;
- wherein the target gene encodes an angiogenesis inhibitor, a tumor-specific antigen or a cytokine;
- which method comprises administering to said mammalian host an effective amount of a selected ligand capable of binding to the chimeric protein to effect observable expression of the target gene.
3 more elements
A method for treating MS episodes in a mammalian host organism containing cells which:
- contain (a) a first DNA construct or pair of first DNA constructs encoding chimeric proteins comprising (i) at least one receptor domain capable of binding to a selected ligand and (ii) another protein domain, heterologous with respect to the receptor domain, and
- (b) a target gene encoding beta-interferon under the expression control of a transcriptional control element responsive to binding of ligand to the ligand binding domain;
- and
- which express the target gene, following exposure to the selected ligand;
- which method comprises administering to said mammalian host an effective amount of a selected ligand capable of binding to the chimeric protein to effect observable expression of the target beta-interferon gene.
2 more elements
A method for treating HIV infection in a mammalian host organism containing cells which:
- contain (a) a first DNA construct or pair of first DNA constructs encoding chimeric proteins comprising (i) at least one receptor domain capable of binding to a selected ligand and (ii) another protein domain, heterologous with respect to the receptor domain, and
- (b) a target gene under the expression control of a transcriptional control element responsive to binding of ligand to the ligand binding domain;
- and
- which express the target gene, following exposure to the selected ligand;
- wherein the target gene encodes a ribozyme or antisense message directed against an HIV nucleotide sequence;
- which method comprises administering to said mammalian host an effective amount of a selected ligand capable of binding to the chimeric protein to effect observable expression of the target gene.
3 more elements
Dependencies are inferred from the claim text.